Dabigatran versus warfarin in patients with atrial fibrillation

Cited by (1,022)

Items 301–400 of 1,022

1. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch
   Sam Schulman, Mark Andrew Crowther · 2012 · Blood
2. Old and new oral anticoagulants: Food, herbal medicines and drug interactions
   Alessandro Di Minno, Beatrice Frigerio, Gaia Spadarella, Alessio L. Ravani, Daniela Sansaro, Mauro Amato, Joseph P. Kitzmiller, Mauro Pepi, Elena Tremoli, Damiano Baldassarre · 2017 · Blood Reviews
3. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary
   Jan Steffel, Peter B. Verhamme, Tatjana Potpara, Pierre Albaladejo, Matthias Antz, Lien Desteghe, Karl Georg Hæusler, Jonas Oldgren, Holger Reinecke, Vanessa Roldán et al. · 2018 · EP Europace
4. New Anticoagulants
   John W. Eikelboom, Jeffrey Ian Weitz · 2010 · Circulation
5. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran
   Viktoria Moschetti, Stephen H. Norris, Joachim Stangier, Michael Schmohl, Joanne van Ryn, Benjamin J. Lang, Steven Ramael, Paul A. Reilly, Stephan Glund · 2015 · Thrombosis and Haemostasis
6. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update
   Edith A. Nutescu, Ittiporn Chuatrisorn, Erika L. Hellenbart · 2011 · Journal of Thrombosis and Thrombolysis
7. Anticoagulant Options — Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran
   B. Nhi Beasley, Ellis F. Unger, Robert Temple · 2011 · New England Journal of Medicine
8. Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi
   Austin A. Robinson, Cory Ross Trankle, Grayson C. Eubanks, Christopher L. Schumann, Paul Thompson, Ryan L. Wallace, Shouri Gottiparthi, Benjamin K. Ruth, Christopher M. Kramer, Michael Salerno et al. · 2020 · JAMA Cardiology
9. Atrial Fibrillation
   PETER J. ZIMETBAUM · 2017 · Annals of Internal Medicine
10. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism
    Manuj Sharma, Victoria R. Cornelius, Jignesh Prakash Patel, Graham Davies, Mariam Molokhia · 2015 · Circulation
11. PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease
    Paul Khairy, George F. Van Hare, Seshadri Balaji, Charles I. Berul, Frank Cecchin, Mitchell I. Cohen, Curt J. Daniels, Barbara J. Deal, Joseph A. Dearani, Natasja M. S. de Groot et al. · 2014 · Canadian Journal of Cardiology
12. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options—a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference
    Paulus F. Kirchhof, Gregory Y.H. Lip, Isabelle C. Van Gelder, Jeroen Joost Bax, Elaine M. Hylek, Stefan Kääb, Ulrich Schotten, Karl Wegscheider, Giuseppe Boriani, Axel Brandes et al. · 2011 · EP Europace
13. Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial
    Daniel E. Singer, Anne S. Hellkamp, Jonathan Paul Piccini, Kenneth W. Mahaffey, Yuliya V. Lokhnygina, Guohua Pan, Jonathan L. Halperin, Richard Clinton Becker, GÜNTER E. BREITHARDT, Graeme J. Hankey et al. · 2013 · Journal of the American Heart Association
14. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease
    Álvaro Avezum, Renato D. Lópes, Phillip J. Schulte, Fernando Tomas Lanas, Bernard John Gersh, Michael Hanna, Prem Pais, Çetin Erol, Rafael Díaz, Maria Cecilia Bahit et al. · 2015 · Circulation
15. Trends in the prescription of novel oral anticoagulants in UK primary care
    Simone Y. Loo, Sophie Dell’Aniello, Laëtitia Huiart, Christel Renoux · 2017 · British Journal of Clinical Pharmacology
16. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation
    David Julian Seiffge, David John Werring, Maurizio Paciaroni, Jesse Dawson, Steven J. Warach, Truman John Milling, Stefan T. Engelter, Urs Fischer, Bo G Norrving · 2018 · The Lancet Neurology
17. Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation
    Greg Flaker, Renato D. Lópes, Sana M. Al‐Khatib, Antonio G. Hermosillo, Stefan Hans Hohnloser, Brian Tinga, Jun Zhu, Puneet Mohan, David A. Garcia, Jozef Bartúnek et al. · 2013 · Journal of the American College of Cardiology
18. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation
    Peter A. Noseworthy, Xiaoxi Yao, Neena S. Abraham, Lindsey R. Sangaralingham, Robert D. McBane, Nilay D. Shah · 2016 · CHEST Journal
19. Patients with atrial fibrillation and coronary artery disease – Double trouble
    Ewelina Michniewicz, Elżbieta Młodawska, Paulina Łopatowska, Anna Tomaszuk−Kazberuk, Jolanta Małyszko · 2017 · Advances in Medical Sciences
20. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
    Dominick Joseph Angiolillo, Shaun G. Goodman, Deepak L. Bhatt, John W. Eikelboom, Matthew J. Price, David J. Moliterno, Christopher Paul Cannon, Jean‐François Tanguay, Christopher Bull Granger, Laura Mauri et al. · 2018 · Circulation
21. Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry
    Masaharu Akao, Yeong‐Hwa Chun, Hiromichi Wada, Masahiro Esato, Tetsuo Hashimoto, Mitsuru Abe, Koji Hasegawa, Hikari Tsuji, Keizo Furuke · 2013 · Journal of Cardiology
22. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)
    Ajay K. Kakkar, Iris Mueller, Jean‐Pierre Bassand, David Andrew Fitzmaurice, Samuel Zachary Goldhaber, Shinya Goto, Sylvia K. Haas, Werner Hacke, Gregory Y.H. Lip, Lorenzo Giovanni Mantovani et al. · 2011 · American Heart Journal
23. Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation
    Kang-Ling Wang, Gregory Y.H. Lip, Shing‐Jong Lin, Chern‐En Chiang · 2015 · Stroke
24. Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality
    Taku Inohara, Ying Xian, Li Liang, Roland Matsouaka, Jeffrey L. Saver, Eric Edward Smith, Lee H. Schwamm, Mathew J. Reeves, Adrian F. Hernandez, Deepak L. Bhatt et al. · 2018 · JAMA
25. 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation
    Jason G. Andrade, Atul Verma, L. Brent Mitchell, Ratika Parkash, Kori Leblanc, Clare L. Atzema, Jeff S. Healey, Alan Bell, John A. Cairns, Stuart J. Connolly et al. · 2018 · Canadian Journal of Cardiology
26. An Expert Consensus Document on the Management of Cardiovascular Manifestations of Fabry Disease
    Aleš Linhart, Dominique Paul Germain, Iacopo Olivotto, Mohammed Majid Akhtar, Aris Anastasakis, Derralynn A. Hughes, Mehdi Namdar, Maurizio Pieroni, Albert Alain Hagège, Franco Cecchi et al. · 2020 · European Journal of Heart Failure
27. STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management
    Pierre R. Tibi, Robert Scott McClure, Jiapeng Huang, Robert A. Baker, David C Fitzgerald, C. David Mazer, Marc E. Stone, Danny Chu, Alfred H. Stammers, Tim Dickinson et al. · 2021 · The Annals of Thoracic Surgery
28. Age as a Risk Factor for Stroke in Atrial Fibrillation Patients
    Marinigh, Ricarda, Lip, Gregory Y.H., Fiotti, Nicola, Giansante, Carlo, Lane, Deirdre A. · 2010 · Journal of the American College of Cardiology
29. AMPK: Potential Therapeutic Target for Ischemic Stroke
    Shuai Jiang, Tian Xiang Li, Ting Ji, Wei Yi, Zhi Ping Yang, Simeng Wang, Yang Yang, Chunhu Gu · 2018 · Theranostics
30. N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation
    Hijazi, Ziad, Wallentin, Lars, Siegbahn, Agneta, Andersson, Ulrika, Christersson, Christina, Ezekowitz, Justin, Gersh, Bernard J., Hanna, Michael, Hohnloser, Stefan, Horowitz, John et al. · 2013 · Journal of the American College of Cardiology
31. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure
    Jeff S. Healey, Martina Brueckmann, John W. Eikelboom, Michael D. Ezekowitz, Mandy Fraessdorf, Herbert Noack, Jonas Oldgren, Paul A. Reilly, Alex C. Spyropoulos, Lars C. Wallentin et al. · 2014 · Thrombosis and Haemostasis
32. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross‐sectional pharmacodynamic study based on peak and trough plasma levels
    Emily M. Hawes, Allison Mary Deal, D. Funk‐Adcock, Robert C. Gosselin, C. Jeanneret, Abigail M. Cook, Jeff Taylor, Herbert C. Whinna, Anne M Winkler, Stephan Moll · 2013 · Journal of Thrombosis and Haemostasis
33. Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations
    Paul A Yates, Victor L. Villemagne, Kathryn A. Ellis, Patricia M. Desmond, Colin Louis Masters, Christopher Cleon Rowe · 2014 · Frontiers in Neurology
34. Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010–2017
    Junya Zhu, G. Caleb Alexander, Saman Nazarian, Jodi B Segal, Albert W. Wu · 2018 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
35. Changes in Renal Function in Patients With Atrial Fibrillation
    Michael Böhm, Michael D. Ezekowitz, Stuart J. Connolly, John W. Eikelboom, Stefan Hans Hohnloser, Paul A. Reilly, Helmut Schumacher, Martina Brueckmann, Stephan Henrik Schirmer, Mario T. Kratz et al. · 2015 · Journal of the American College of Cardiology
36. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review
    Borre, Ethan, Goode, Adam, Raitz, Giselle, Shah, Bimal, Lowenstern, Angela, Chatterjee, Ranee, Sharan, Lauren, Allen LaPointe, Nancy, Yapa, Roshini, Davis, J. et al. · 2018 · Thrombosis and Haemostasis
37. Guideline on the management of bleeding in patients on antithrombotic agents
    Mike Makris, Joost J. van Veen, Robert Campbell Tait, Andrew David Mumford, Michael Laffan · 2012 · British Journal of Haematology
38. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline)
    L. Samüel Wann, Anne B. Curtis, Craig T. January, Kenneth A. Ellenbogen, James E. Lowe, N.A. Mark Estes, Richard L. Page, Michael D. Ezekowitz, David J. Slotwiner, Warren M. Jackman et al. · 2010 · Journal of the American College of Cardiology
39. Untitled work
    Goodman · 2014 · 10.1016/j.jacc.2013.11.013
40. Assessing bleeding risk in patients taking anticoagulants
    Marwa Shoeb, Margaret C. Fang · 2013 · Journal of Thrombosis and Thrombolysis
41. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA)
    Adam J. Rose, Elaine M. Hylek, Al Ozonoff, Arlene S. Ash, Joel I. Reisman, Dan R. Berlowitz · 2010 · Journal of Thrombosis and Haemostasis
42. New oral anticoagulant drugs in cardiovascular disease
    Gregory Y.H. Lip, Karlheinz Peter, Ingo Ahrens · 2010 · Thrombosis and Haemostasis
43. Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study
    Esther W. Chan, Wallis C. Y. Lau, Wai K. Leung, Michael T.C. Mok, Ying He, Teresa S. M. Tong, Ian Chi Kei Wong · 2015 · Gastroenterology
44. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial
    Paulus F. Kirchhof, Benjamin F. Blank, Melanie Calvert, A. John Camm, GREGORY I. CHLOUVERAKIS, Hans‐Christoph Diener, Andreas Goette, Andrea Huening, Gregory Y.H. Lip, EMMANUEL N. SIMANTIRAKIS et al. · 2017 · American Heart Journal
45. Pros and cons of new oral anticoagulants
    Kenneth Alan Bauer · 2013 · Hematology
46. Adherence to dabigatran therapy and longitudinal patient outcomes: Insights from the Veterans Health Administration
    Supriya Shore, Evan Carey, Mintu P. Turakhia, Cynthia Anne Jackevicius, Fran Cunningham, Louise Pilote, Steven M. Bradley, Thomas M. Maddox, Gary K. Grunwald, Anna E. Barón et al. · 2014 · American Heart Journal
47. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter
    M. S. Arakelyan, Leo A. Bockeria, Elena Vasilieva, Golitsyn Sp, Elena Zelikovna Golukhova, M. V. Gorev, Karapet V. Davtyan, Oksana M. Drapkina, Кропачева Екатерина Станиславовна, Е. А. Kuchinskaya et al. · 2021 · Russian Journal of Cardiology
48. Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF
    Kevin E. Chan, Robert Patrick Giugliano, Manesh R. Patel, Stuart Abramson, Meg Jardine, Sophia J. Zhao, Vlado Perkovic, Franklin W. Maddux, Jonathan Paul Piccini · 2016 · Journal of the American College of Cardiology
49. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation
    Ying Xian, Emily Claire O'Brien, Li Liang, Haolin Xu, Lee H. Schwamm, Gregg C. Fonarow, Deepak L. Bhatt, Eric Edward Smith, DaiWai M. Olson, Lesley Maisch et al. · 2017 · JAMA
50. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding
    Ray, Wayne A., Chung, Cecilia P., Murray, Katherine T., Smalley, Walter E., Daugherty, James R., Dupont, William D., Stein, C. Michael · 2018 · JAMA
51. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis
    Gregory Y.H. Lip, Felicita Andreotti, Laurent Fauchier, Kurt Huber, Elaine M. Hylek, Eve Knight, Deirdre A. Lane, Marcel M Levi, Francisco R. Marín, Gualtiero Palareti et al. · 2011 · EP Europace
52. Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation
    Tze‐Fan Chao, Chia‐Jen Liu, Yenn‐Jiang Lin, Shih‐Lin Chang, Li‐Wei Lo, Yu‐Feng Hu, Ta‐Chuan Tuan, Jo‐Nan Liao, Fa‐Po Chung, Tzeng‐Ji Chen et al. · 2018 · Circulation
53. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines
    Andrew Veitch, Geoffroy Vanbiervliet, Anthony Gershlick, Christian Boustière, Trevor P Baglin, Lesley‐Ann Smith, Franco Radaelli, Evelyn Knight, Ian Mark Gralnek, Cesare Hassan et al. · 2016 · Endoscopy
54. Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)
    Gregory Y.H. Lip, António Coca, Thomas Kahan, Giuseppe Boriani, Antonis S. Manolis, Michael Hecht Olsen, Ali̇ Oto, Tatjana Potpara, Jan Steffel, Francisco R. Marín et al. · 2017 · EP Europace
55. Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke
    Rizos, Timolaos, Güntner, Janina, Jenetzky, Ekkehart, Marquardt, Lars, Reichardt, Christine, Becker, Rüdiger, Reinhardt, Roland, Hepp, Thomas, Kirchhof, Paulus, Aleynichenko, Elena et al. · 2012 · Stroke
56. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice
    Gregory Y.H. Lip, Hans‐Christoph Diener, Martina Brueckmann, Joanne van Ryn, Andreas Clemens, Menno Volkert Huisman · 2012 · Thrombosis and Haemostasis
57. Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology
    Massimo Francesco Piepoli, Ana Abreu, Christian Albus, Marco Ambrosetti, Carlos Brotons, Alberico Luigi Catapano, Ugo Corrà, Bernard Cosyns, Christi Deaton, Ian M Graham et al. · 2019 · European Journal of Preventive Cardiology
58. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study
    Stuart J. Connolly, Lars C. Wallentin, Michael D. Ezekowitz, John W. Eikelboom, Jonas Oldgren, Paul A. Reilly, Martina Brueckmann, Janice M. Pogue, Marco Alings, John V. Amerena et al. · 2013 · Circulation
59. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries
    Benjamin Adam Steinberg, Haiyan Gao, Peter J. Shrader, Karen Pieper, Laine Elliott Thomas, A. John Camm, Michael D. Ezekowitz, Gregg C. Fonarow, Bernard John Gersh, Samuel Zachary Goldhaber et al. · 2017 · American Heart Journal
60. Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation
    Lars C. Wallentin, Renato D. Lópes, Michael Hanna, Laine Elliott Thomas, Anne S. Hellkamp, Sunil Nepal, Elaine M. Hylek, Sana M. Al‐Khatib, John Hunter Alexander, Marco Alings et al. · 2013 · Circulation
61. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies
    Apostolos Tzikas, David R. Holmes, Sameer A. Gafoor, Carlos Eduardo Ruiz, Carina Blomström‐Lundqvist, Hans‐Christoph Diener, Riccardo Cappato, Saibal Kar, Randal J. Lee, Robert A. Byrne et al. · 2016 · EP Europace
62. Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin
    Wolfgang G. Eisert, Norbert H. Hauel, Joachim Stangier, Wolfgang Wienen, Andreas Clemens, Joanne van Ryn · 2010 · Arteriosclerosis Thrombosis and Vascular Biology
63. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation
    George Ntaios, Vasileios Papavasileiou, Konstantinos P. Makaritsis, Konstantinos N. Vemmos, Patrik Michel, Gregory Y.H. Lip · 2017 · Stroke
64. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
    Joshua Pink, S. Lane, Munir Pirmohamed, Dyfrig Arwyn Hughes · 2011 · BMJ
65. Comorbidity of atrial fibrillation and heart failure
    Liang‐Han Ling, Peter M. Kistler, Jonathan M. Kalman, RICHARD JOHN SCHILLING, Ross Jacob Hunter · 2015 · Nature Reviews Cardiology
66. Early Safety and Efficacy of Percutaneous Left Atrial Appendage Suture Ligation
    Matthew J. Price, Douglas N Gibson, Steven Joseph Yakubov, Jason C. Schultz, Luigi Di Biase, Andrea Natale, J. David Burkhardt, Ashish Pershad, Timothy Byrne, Brett Gidney et al. · 2014 · Journal of the American College of Cardiology
67. Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation
    Yukiko Matsumura‐Nakano, Satoshi Shizuta, Akihiro Komasa, Takeshi Morimoto, Hisaki Masuda, Hiroki Shiomi, Koji Goto, Kentaro Nakai, Hisashi Ogawa, Atsushi Kobori et al. · 2019 · Circulation
68. 2024 Clinical practice guidelines for Chronic heart failure
    Albert S. Galyavich, Sergey N. Tereshchenko, T. M. Uskach, Fail T. Ageev, D. M. Aronov, G. P. Arutyunov, Yu. L. Begrambekova, Yu. N. Belenkov, Sergey Anatol'evich Boytsov, Marina Gennad'evna Bubnova et al. · 2024 · Russian Journal of Cardiology
69. Patent foramen ovale
    Shunichi Homma, Steven Russell Messe, Tatjana Rundek, Yee‐Ping Sun, Jennifer Franke, Karina W. Davidson, Horst Sievert, Ralph L. Sacco, Marco R. Di Tullio · 2016 · Nature Reviews Disease Primers
70. Atrial Fibrillation
    Darae Ko, Mina K. Chung, Peter T. Evans, Emelia J. Benjamin, Robert H. Helm · 2024 · JAMA
71. Effective elimination of dabigatran by haemodialysis
    Stephan Formella, Erol Wiegert, Viktoria Moschetti, Torsten Slowinski, Hans‐H. Neumayer, Karl‐Heinz Liesenfeld, Thorsten Lehr, Sebastian Härtter, Jeffrey E. Friedman, Dmytro Khadzhynov et al. · 2013 · Thrombosis and Haemostasis
72. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding
    Theodore Earl Warkentin, Peter J. Margetts, Stuart J. Connolly, Andre L. Lamy, Chris Ricci, John W. Eikelboom · 2012 · Blood
73. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial
    Renato D. Lópes, Sana M. Al‐Khatib, Lars C. Wallentin, Hongqiu Yang, Jack Ansell, Maria Cecilia Bahit, Raffaele De Caterina, Paul Dorian, J. Donald Easton, Çetin Erol et al. · 2012 · The Lancet
74. Rates of hemorrhage during warfarin therapy for atrial fibrillation
    Tara Gomes, Muhammad Mamdani, Anne Marie Holbrook, John Michael Paterson, Chelsea Hellings, David Nelson Juurlink · 2012 · Canadian Medical Association Journal
75. Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
    Benjamin Adam Steinberg, Peter J. Shrader, Karen S. Pieper, Laine Elliott Thomas, Larry A. Allen, Jack Ansell, Paul S. Chan, Michael D. Ezekowitz, Gregg C. Fonarow, James V. Freeman et al. · 2018 · Journal of the American Heart Association
76. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants
    Pancholy, Samir B., Sharma, Parikshit S., Pancholy, Dipti S., Patel, Tejas M., Callans, David J., Marchlinski, Francis E. · 2014 · The American Journal of Cardiology
77. Warfarin in atrial fibrillation patients with moderate chronic kidney disease
    Hart, Robert G., Pearce, Lesly A., Asinger, Richard W., Herzog, Charles A. · 2011 · Clinical Journal of the American Society of Nephrology
78. Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting
    John W. Eikelboom, Peter B. Berger, David R. Holmes, Deepak L. Bhatt, Richard Clinton Becker, Dominick Angiolill, David P. Faxon, David J. Moliterno · 2011 · Thrombosis and Haemostasis
79. Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation— Quality and Cost Implications
    Nihar R. Desai, Alexis A. Krumme, Sebastian Schneeweiß, William H. Shrank, Gregory E. Brill, Edmund J. Pezalla, Claire M. Spettell, Troyen A. Brennan, Olga S. Matlin, Jerry Avorn et al. · 2014 · The American Journal of Medicine
80. New Oral Anticoagulants and the Cancer Patient
    Nicholas James Short, Jean M. Connors · 2013 · The Oncologist
81. The Use of Dabigatran in Elderly Patients
    Matthieu M. Legrand · 2011 · Archives of Internal Medicine
82. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective
    Anuraag Kansal, Stuart J. Connolly, Siyang Peng, John E. Linnehan, Carole Bradley-Kennedy, Jonathan Plumb, Sonja V. Sorensen · 2011 · Thrombosis and Haemostasis
83. Anticoagulants: A Review of the Pharmacology, Dosing, and Complications
    Mohammed Alquwaizani, Leo Francis Buckley, Christopher Adams, John R. Fanikos · 2013 · Current Emergency and Hospital Medicine Reports
84. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy
    Stefan Agewall, Marco Cattaneo, J.‐P. Collet, Felicita Andreotti, Gregory Y.H. Lip, Freek W.A. Verheugt, Kurt Huber, Erik Lerkevang Grove, João Morais, Steen Husted et al. · 2013 · European Heart Journal
85. Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban
    Inna Y. Gong, Richard B. Kim · 2013 · Canadian Journal of Cardiology
86. Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
    Sean D. Pokorney, Jonathan Paul Piccini, Susanna R. Stevens, Manesh R. Patel, Karen S. Pieper, Jonathan L. Halperin, GÜNTER E. BREITHARDT, Daniel E. Singer, Graeme J. Hankey, Werner Hacke et al. · 2016 · Journal of the American Heart Association
87. Unexpectedly High Incidence of Stroke and Left Atrial Appendage Thrombus Formation After Electrical Isolation of the Left Atrial Appendage for the Treatment of Atrial Tachyarrhythmias
    Andreas Rillig, Roland Richard Tilz, Tina Lin, Thomas Fink, Christian-Hendrik H. Heeger, Anita Arya, Andreas Metzner, Shibu Mathew, Erik Wißner, Hisaki Makimoto et al. · 2016 · Circulation Arrhythmia and Electrophysiology
88. Trends in Oral Anticoagulant Use Among 436 864 Patients With Atrial Fibrillation in Community Practice, 2011 to 2020
    Ann Marie Návar, Ahmed A. Kolkailah, Robert A. Overton, Nishant P. Shah, Justin F. Rousseau, Greg C. Flaker, Michael Patrick Pignone, Eric David Peterson · 2022 · Journal of the American Heart Association
89. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis
    Oldgren, J., Wallentin, L., Alexander, J. H., James, S., Jonelid, B., Steg, G., Sundstrom, J. · 2013 · European Heart Journal
90. Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms
    Francesco Violi, Elsayed Z. Soliman, Pasquale Pignatelli, Daniele Pastori · 2016 · Journal of the American Heart Association
91. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis
    Jonathan A C Sterne, Pritesh N. Bodalia, Peter A. Bryden, Philippa A. Davies, José A López-López, George N. Okoli, Howard H. Z. Thom, Deborah M Caldwell, Sofia Dias, Diane Eaton et al. · 2017 · Health Technology Assessment
92. The p -Value Requires Context, Not a Threshold
    Rebecca A. Betensky · 2019 · The American Statistician
93. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension
    Manolis, Athanasios J., Rosei, Enrico Agabiti, Coca, Antonio, Cifkova, Renata, Erdine, Serap E., Kjeldsen, Sverre, Lip, Gregory Y.H., Narkiewicz, Krzysztof, Parati, Gianfranco, Redon, Josep et al. · 2012 · Journal of Hypertension
94. Severe Renal Impairment and Stroke Prevention in Atrial Fibrillation
    Marinigh, Ricarda, Lane, Deirdre A., Lip, Gregory Y.H. · 2011 · Journal of the American College of Cardiology
95. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial
    Breithardt, Günter, Baumgartner, Helmut, Berkowitz, Scott D., Hellkamp, Anne S., Piccini, Jonathan P., Stevens, Susanna R., Lokhnygina, Yuliya, Patel, Manesh R., Halperin, Jonathan L., Singer, Daniel E. et al. · 2014 · European Heart Journal
96. Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial
    Jonas Oldgren, Marco Alings, Harald Darius, Hans-Christoph Diener, John Eikelboom, Michael D. Ezekowitz, Gabriel Kamensky, Paul A. Reilly, Sean Yang, Salim Yusuf et al. · 2011 · Annals of Internal Medicine
97. Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques
    Pierre Amarenco, Stephen M. Davis, Elizabeth F. Jones, Ariel A. Cohen, Wolf‐Dieter Heiss, Markku Kaste, Cédric Laouenan, Dennis Young, Malcolm Robert Macleod, Geoffrey Alan Donnan et al. · 2014 · Stroke
98. The State of the Art
    Daniel P. Morin, Michael L. Bernard, Christopher A. Madias, Paul A. Rogers, Sudarone Thihalolipavan, N.A. Mark Estes · 2016 · Mayo Clinic Proceedings
99. New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists
    Francesco Scaglione · 2013 · Clinical Pharmacokinetics
100. Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism
     Soheir S. Adam, Jennifer R McDuffie, Thomas L. Ortel, John W Williams · 2012 · Annals of Internal Medicine